Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

jean-philippe Jacquin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

J.P. Jacquin1, L. Uwer2, A. Savignoni3, J. Ferrero4, A. Lortholary5, D. Solub6, H. Attar-Rabia7, S. Deblay7, S. Pibre7, Y. Belkacemi8

Author affiliations

  • 1 Oncology Unit, Institut de Cancérologie de la Loire, Lucien Neuwirth, 42270 - Saint-etienne/FR
  • 2 Oncology Unit, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandœuvre-lès-Nancy/FR
  • 3 Pole Biométrie, Institut Curie, 75005 - Paris/FR
  • 4 Oncology Unit, Centre Antoine Lacassagne, 6100 - Nice/FR
  • 5 Oncology Unit, Hopital prové du Confluent, Institut de cancérologie Catherine de Sienne, 44202 - Nantes/FR
  • 6 Oncology Unit, Hôpitaux de Chartres, 28018 - Chartres/FR
  • 7 Oncology Unit, Roche S.A.S - France, 92100 - Boulogne-Billancourt Cedex/FR
  • 8 Henri Mondor Breast Cancer Center And Department Of Radiation oncology, AP-HP, Henri Mondor University Hospital, University of Paris-Est Créteil (UPEC), 94010 - Créteil/FR
More

Resources

Abstract 3742

Background

The HERMIONE study was conducted to assess, in HER2-positive early breast cancer, the safety profile of subcutaneous formulation of trastuzumab (SC T) in real life in France.

Methods

This prospective, multicenter, noninterventional study included 511 patients planned to be treated in both neoadjuvant and adjuvant settings with a follow-up (FU) of 12 months maximum. The safety analyses concerned 505 patients, either naïve (40.4%) or non-naïve (59.6%) of intravenous trastuzumab (IV T). According to routine practice, patients received concomitant locoregional radiotherapy (68.7%), endocrine therapy (59.9%) and chemotherapy (37.8%). Primary endpoint was the description of systemic and local Adverse Events (AEs) of SC T assessed by NCI-CTCAE. Congestive Heart Failure (CHF), hepatobiliary toxicity and suspected transmission of an infectious agent by SC T were AEs of Special Interest (AESIs). Secondary endpoints included description of patients, disease characteristics and modalities of SC T administration. Quality of life (QoL) was assessed by QLQ-C30.

Results

Patients were included in 101 sites between January and November 2015. The median age was 58 years. Over the FU period, AEs occurred in 422 patients (83.6%): 92 AEs (3.8%) were grade ≥ 3, 76 (3.1%) were serious, 87 (3.6%) were AESIs and 336 (13.7%) were related to SC T. Most frequent AEs (> 10% of patients) were asthenia, arthralgia, radiation skin injury, myalgia, hot flush and diarrhea. Main grade ≥3 events were radiation skin injury (1.8% of patients) and febrile neutropenia (1.4%). Serious AEs (SAEs) included febrile neutropenia (9.2% of SAEs) and pulmonary embolism (6.6%). Main AESI was CHF in 11.5% of patients and was related to SC T only in 4.5%. Injection site pain was the main SC Trelated AE (9.1% of patients). Few AEs (1.4%) led to permanent SC T discontinuation. Only 1 death assessed as not related to SC T (pulmonary thromboembolism) was reported. QoL analyses showed no deterioration of global health status.

Conclusions

The Hermione study showed that the safety of SC T (HERCEPTIN®) in a real-life setting is consistent with the known profile, without new safety concerns or QoL deterioration.

Clinical trial identification

NCT02286362.

Legal entity responsible for the study

Hoffmann-La Roche.

Funding

Hoffmann-La Roche.

Editorial Acknowledgement

Stéphanie Mohsen, Aixial.

Disclosure

H. Attar-Rabia, S. Deblay, S. Pibre: Roche employee. Y. Belkacemi: Honoraria and consulting: Astellas, Roche, Genomic Health. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings